Skip to content
Inciteful Med
Resources About us Ask a Question

How to Manage Myeloma Treatment Neuropathy?

Published: | Updated:

Peripheral neuropathy causes tingling, numbness, and pain in the hands and feet, and is a common side effect of multiple myeloma treatments like bortezomib. It is critical to report these symptoms to your doctor immediately so they can adjust your treatment to prevent permanent nerve damage.

Key Takeaways

  • • Peripheral neuropathy is a common side effect of multiple myeloma medications like bortezomib and thalidomide.
  • • Symptoms include numbness, tingling, burning pain, and muscle weakness in the hands and feet.
  • • Reporting symptoms to your doctor early is critical to prevent permanent, disabling nerve damage.
  • • Doctors can manage neuropathy by reducing medication doses, changing treatment schedules, or changing how the drug is administered.
  • • Patients experiencing numbness must take extra daily precautions to prevent falls and avoid foot injuries.

Tingling, numbness, and a “pins and needles” sensation in your toes are very common side effects of certain multiple myeloma medications [1][2]. This condition is called peripheral neuropathy, which is nerve damage that typically starts in the hands or feet. If you are experiencing these sensations, you are not alone, but it is critical that you report them to your care team immediately [3][4].

What Does Peripheral Neuropathy Feel Like?

Peripheral neuropathy primarily affects the sensory nerves in your extremities, though it can sometimes affect the nerves controlling your muscles [5]. You might experience:

  • Numbness or a loss of feeling in your toes, feet, or fingers [6].
  • Tingling or a “pins and needles” sensation [6].
  • Burning pain or a sharp, electric-shock type of discomfort [5][7].
  • Heightened sensitivity to touch or temperature changes [6].
  • Muscle weakness, such as difficulty gripping objects or a dragging feeling in your foot (often called foot drop) [3].

Why Does It Happen?

While the myeloma proteins themselves can occasionally cause nerve issues, peripheral neuropathy is most often caused by the cancer treatments rather than the disease itself [8][9][10]. The most common culprits are:

  • Proteasome Inhibitors: Medications like bortezomib (brand name Velcade) frequently cause neuropathy [1][11].
  • Immunomodulatory Drugs: Older drugs like thalidomide also have a high rate of causing nerve damage [12].

These medications can damage the long nerve fibers that travel to your toes and fingers [13].

Why Early Reporting Is Critical

You might be tempted to ignore mild tingling because you don’t want to complain or interrupt your cancer treatment. However, ignoring peripheral neuropathy can be dangerous.

When neuropathy is caught early, your doctor can make adjustments that give you the best chance to prevent permanent damage, and symptoms can often improve or resolve [11][12]. If the nerve damage is allowed to progress, it can become permanent and disabling, affecting your balance, walking, and ability to perform daily tasks like buttoning a shirt [3][4]. Reporting symptoms right away allows your doctor to make minor adjustments to protect your nerves while still effectively treating your myeloma [3].

How Your Care Team Can Help

There are several strategies your doctor can use to manage peripheral neuropathy without compromising your overall treatment plan:

  • Dose Reduction: Lowering the dose of the medication is a common and effective way to reduce nerve toxicity [1][11].
  • Schedule Changes: Switching from a twice-weekly treatment schedule to a once-weekly schedule can significantly improve your tolerance to the drug and lower the risk of neuropathy [14][15].
  • Changing Administration Route: If you are receiving bortezomib intravenously (IV), switching to a subcutaneous injection (a shot under the skin) can lower the incidence and severity of neuropathy while maintaining the drug’s effectiveness against myeloma [16][17].
  • Treatment Delays: Pausing treatment briefly can give your nerves time to heal before restarting [1][18].

There are also supportive treatments that can help manage the pain and discomfort of neuropathy. Your doctor might prescribe nerve pain medications (like gabapentin or duloxetine), specific vitamins (like B vitamins), or adhesive pain patches [19][20].

Living Safely With Numbness

Because multiple myeloma can weaken your bones, a fall can be devastating. If you have numbness in your feet, you must take extra precautions to avoid injuries you might not feel [3]:

  • Clear trip hazards: Remove loose rugs and clutter from your floors.
  • Inspect your feet daily: Look for cuts, blisters, or sores that you might not have felt.
  • Wear protective shoes: Avoid walking barefoot, even indoors.
  • Test water temperature: Always use your elbow or wrist—not your hand or foot—to check bathwater temperature to avoid burns.

Frequently Asked Questions

Why do my hands and feet tingle after myeloma treatment?
Myeloma medications, particularly proteasome inhibitors like bortezomib, can damage the long nerve fibers traveling to your hands and feet. This condition, called peripheral neuropathy, causes tingling, numbness, and sometimes pain.
Can peripheral neuropathy from myeloma treatment be reversed?
If caught early, symptoms can often improve or resolve with adjustments to your treatment plan. However, if left untreated, the nerve damage can become permanent, which is why it is critical to report symptoms to your doctor immediately.
Will I have to stop my myeloma treatment if I develop nerve pain?
Not necessarily. Your doctor has many strategies to manage neuropathy, such as lowering the drug dose, changing how often you receive treatment, or switching from an IV to a subcutaneous injection, allowing you to safely continue treatment.
What medications help with nerve pain from myeloma treatment?
Your care team can prescribe supportive treatments for nerve discomfort. Common options include nerve pain medications like gabapentin or duloxetine, specific vitamins like B vitamins, and adhesive pain patches.
How can I stay safe at home if my feet are numb?
If you have numbness in your feet, you must take extra precautions to avoid falls and injuries. You should clear trip hazards at home, inspect your feet daily for sores, wear protective shoes indoors, and test bathwater temperature with your elbow.

Questions for Your Doctor

  • • What changes can we make to my dose or treatment schedule to stop this neuropathy from getting worse?
  • • If I am on bortezomib, am I a candidate to switch from intravenous to a subcutaneous injection to help my nerves?
  • • Are there specific nerve pain medications, like gabapentin, or supplements that might help manage my symptoms?
  • • What specific warning signs or changes in my neuropathy symptoms mean I need to call you before my next appointment?
  • • How long does it typically take to see improvement in my nerve symptoms after we adjust my treatment?

Questions for You

  • • When did I first notice the tingling or numbness, and has it spread further up my feet or hands?
  • • Are my symptoms getting in the way of daily tasks like walking, balancing, or picking up objects?
  • • Have I checked my home for tripping hazards or started wearing protective shoes indoors?
  • • Do my symptoms feel worse right after my treatment, or are they constant?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.

    Li T, Timmins HC, King T, et al.

    Hematological oncology 2020; (38(3)):229-243 doi:10.1002/hon.2706.

    PMID: 31873944
  2. 2

    The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.

    Beijers AJ, Oerlemans S, Mols F, et al.

    Annals of hematology 2017; (96(4)):653-663 doi:10.1007/s00277-017-2927-8.

    PMID: 28116479
  3. 3

    Chemotherapy-Induced Peripheral Neuropathy Impacts Quality of Life and Activities of Daily Living of Brazilian Multiple Myeloma Patients.

    de Miranda Drummond PL, Dos Santos RMM, Silveira LP, et al.

    Current drug safety 2024; (19(3)):356-367 doi:10.2174/1574886318666230817162424.

    PMID: 37592770
  4. 4

    Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.

    Maschio M, Zarabla A, Maialetti A, et al.

    Integrative cancer therapies 2018; (17(4)):1115-1124 doi:10.1177/1534735418803758.

    PMID: 30295079
  5. 5

    Chemotherapy-Induced Peripheral Neuropathy and its Impact on Health-Related Quality of Life among Multiple Myeloma Patients: A Single-Center Experience.

    Shaheen NA, Alqahtani M, Alawbthani NS, et al.

    Indian journal of palliative care 2020; (26(4)):506-511 doi:10.4103/IJPC.IJPC_233_19.

    PMID: 33623313
  6. 6

    Earlier onset of chemotherapy-induced neuropathic pain in females by ICAM-1-mediated accumulation of perivascular macrophages.

    Chen L, Zou X, Liu CC, et al.

    Science advances 2025; (11(16)):eadu2159 doi:10.1126/sciadv.adu2159.

    PMID: 40238872
  7. 7

    Bone Health, Pain, and Mobility: Evidence-Based Recommendations for Patients With Multiple Myeloma

    Rome S, Noonan K, Bertolotti P, et al.

    Clinical journal of oncology nursing 2017; (21(5 Suppl)):47-59 doi:10.1188/17.CJON.S5.47-59.

    PMID: 28945729
  8. 8

    Multiple Myeloma Plasmacytoid Infiltration of the Gallbladder Presenting as Acute Cholecystitis.

    Alyass F, Narh-Martey PN

    CRSLS : MIS case reports from SLS 2021; (8(4)) doi:10.4293/CRSLS.2021.00049.

    PMID: 36017061
  9. 9

    Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders.

    Byun JM, Kwon YN, Koh Y, et al.

    Scientific reports 2019; (9(1)):16769 doi:10.1038/s41598-019-53289-w.

    PMID: 31727997
  10. 10

    Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.

    Luo J, Gagne JJ, Landon J, et al.

    European journal of cancer (Oxford, England : 1990) 2017; (70()):22-33 doi:10.1016/j.ejca.2016.10.018.

    PMID: 27866096
  11. 11

    Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study.

    Yang H, Liu C, Yuan F, Li F

    Scandinavian journal of clinical and laboratory investigation 2021; (81(8)):615-621 doi:10.1080/00365513.2021.1986857.

    PMID: 34648407
  12. 12

    [Thalidomide induced peripheral neuropathy in multiple myeloma patients].

    Banach M, Jurczyszyn A, Skotnicki A

    Przeglad lekarski 2015; (72(11)):629-35.

    PMID: 27012121
  13. 13

    Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors.

    Sogbein O, Paul P, Umar M, et al.

    Life sciences 2024; (358()):123125 doi:10.1016/j.lfs.2024.123125.

    PMID: 39413903
  14. 14

    Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis.

    Hoff FW, Banerjee R, Khan AM, et al.

    Blood cancer journal 2024; (14(1)):52 doi:10.1038/s41408-024-01034-6.

    PMID: 38519476
  15. 15

    Efficacy and Safety of Once-Weekly versus Twice-Weekly Bortezomib in Patients with Hematologic Malignancies: A Meta-analysis with Trial Sequential Analysis.

    Hu B, Zhou Q, Hu YY, et al.

    Pharmacotherapy 2019; (39(6)):697-708 doi:10.1002/phar.2267.

    PMID: 30985015
  16. 16

    Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.

    Mu SD, Ai LS, Qin Y, Hu Y

    Current medical science 2018; (38(1)):43-50 doi:10.1007/s11596-018-1844-y.

    PMID: 30074150
  17. 17

    Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.

    Liu H, Xu R, Huang H

    Experimental and therapeutic medicine 2016; (12(5)):3041-3046 doi:10.3892/etm.2016.3738.

    PMID: 27882113
  18. 18

    Bortezomib in newly diagnosed patients with multiple myeloma: A retrospective analysis from a tertiary care center in India.

    Pragnya C, Linga VG, Thota NK, et al.

    Indian journal of cancer 2015; (52(4)):537-40 doi:10.4103/0019-509X.178388.

    PMID: 26960469
  19. 19

    Glutathione combined with mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study.

    Huang H, Zhao M, Liu X, et al.

    Annals of palliative medicine 2021; (10(12)):12335-12346 doi:10.21037/apm-21-3313.

    PMID: 35016427
  20. 20

    Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series.

    Moreno-Alonso D, Llorens-Torromé S, Corcoy de Febrer B, et al.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2024; (30(4)):752-758 doi:10.1177/10781552241230887.

    PMID: 38415287

This page is for informational purposes only. Always report new numbness or tingling to your oncology team immediately, as early intervention can prevent permanent nerve damage.

Stay up to date

Get notified when new research about Multiple Myeloma is published.

No spam. Unsubscribe anytime.